Oncolytic virus therapy

Details Oncolytic virus therapy Oncolytic virus therapy

2006-10-17

2006-10-17

Canella, Karen A. (Department: 1642)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Virus or bacteriophage

C424S093710, C424S093720

Reexamination Certificate

active

07122182

ABSTRACT:
A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.

REFERENCES:
patent: 5126132 (1992-06-01), Rosenberg
patent: 6207147 (2001-03-01), Hiserodt et al.
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: WO 94/25627 (1994-11-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/29343 (1999-06-01), None
patent: WO 00/62735 (2000-10-01), None
patent: WO 01/19380 (2001-03-01), None
Perkins, In: Basic and Clinical Immunology, Fudenberg et al, Ed., 1978, pp. 177-182.
Termeer et al, Cancer Gene Therapy, 2000, vol. 7, pp. 316-323.
Harfast et al (Journal of Immunology, 1977, vol. 118, pp. 1132-1137).
Schirrmacher et al (Clinical Cancer Research, 1997, vol. 3, pp. 1135-1148).
Dong et al, In: Vaccine Design: The Subunit and Adjuvant Approach, Powell et al, Ed.s, 1995, pp. 625-643.
Bohlen et al, (Blood, 1993, Volt, 82, pp. 1803-1812).
Bonina, et al., “Human Mononuclear Phagocytic Cell Interaction with some Paramyxoviridae”, Giom. Batt. Virol. Immun., LXXVIII, pp. 254-261, 1985.
Faden, et al., “The In Vitro Effect of Newcastle Disease Virus on the Metabolic and Antibacterial Functions of Human Neutrophils”, Blood, vol. 58, No. 2, pp. 221-227, Aug. 1981.
Schimmacher, et al., “Newcastle Disease Virus activates macrophages for anti-tumor activity”, International Journal of Oncology, vol. 16, pp. 363-373, 2000.
Baranowski, et al., “Evolution of Cell Recognition by Viruses”, Science, vol. 292, pp. 1102-1105, May 2001.
Pecora, et al., “Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers”, Journal of Clinical Oncology, vol. 20, No. 9, pp. 2251-2266, May 2002. (esp. last para. on p. 2253, first para. on p. 2254, and first full para. on p. 2262).
“An Intravenous Phase I Trial of Replication-Competent Virus, PV701, in the Treatment of Patients with Advanced Solid Cancers (Abstract #1009)-Dr. Andrew Pecora—Presented May 13, 2001, ImmunoBiology Session American Society of Clinical Oncology—Palace Hotel, San Francisco, California”, transcript pp. 1-10, (esp. first full para. on p. 7 and p. 9).
An Intravenous Phase I Trial of a Replication-Competent Virus, PV701, in the Treatment of Patients with Advanced Solid Cancers slide presentation, May 13, 2001.
Howe, et al., “Virus-Erythrocyte Interactions”, Advances in Virus-Research, vol. 17, pp. 1-50, 1972.
Woodruff, et al., “Virus-Induced Alterations of Lymphoid Tissues II. Lymphocyte Receptors for the Newcastle Disease Virus”, Cellular Immunology, vol. 5, pp. 296-306, 1972.
Woodruff, et al., “Lymphocyte Receptors for Myxoviruses and Paramyxoviruses”, The Journal of Immunology, vol. 112, No. 6, pp. 2176-2183, Jun. 1974.

Affiliated with

Also associated with

Rating

Oncolytic virus therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oncolytic virus therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oncolytic virus therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3641751